Moreover, 18 of the 18 (100%) HER2-positive patients had a clinical T3–4a tumor and 11 of the 76 (14%) HER2-negative patients had a clinical T1–2 tumor (p value = 0.12, Fisher’s exact test). The gene discussed is ERBB2; the disease is neoplasm.